All In Biotech

Drug Trial Radar · NCT01976572

Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

A Randomised, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Oral Doses of Candesartan Cilexetil in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Oct 2013

Primary completion

Jan 2014

Study completion Jan 2014

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Nov 6, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to assess the effects of colestilan on the pharmacokinetic profile of candesartan cilexetil when administered at the same time as, 1 hour before, and 3 hours after the first daily dose of colestilan administered at doses of 5 g three times daily compared to administration of candesartan cilexetil alone, in healthy subjects.

Conditions

  • Hyperphosphatemia
  • Chronic Kidney Disease

Interventions

  • colestilanDrug

  • candesartanDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-t of CandesartanTime frame: 0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose
  2. Cmax of CandesartanTime frame: 0, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit Ltd.

    Leeds, Springfield House Hyde Street, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.